A Phase III Confirmatory Study of K-877 Extended Release Tablet

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

356 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-02-01

Study Completion Date

2021-09-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To investigate the efficacy and safety of K-877 Extended Release (ER) 0.2 mg/day or 0.4 mg/day (once daily) for 12 weeks in dyslipidemia, using K-877 Immediate Release (IR) 0.2 mg/day (twice daily) as a control.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Phase III Long Term Study of K-877 Extended Release Tablet

NCT04716595

Dyslipidemias

COMPLETED PHASE3

A Phase III Confirmatory Study of K-877 (Pemafibrate) in Patients With Hypercholesterolemia and Statin Intolerance

NCT05923281

Hypercholesterolemia

COMPLETED PHASE3

Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Mild or Moderate Renal Impairment

NCT03011450

Severe Hypertriglyceridemia

COMPLETED PHASE3

A Phase 3 Study to Evaluate the Efficacy and Safety of K-877 in Chinese Patients With High TG and Low HDL-C

NCT04998981

Hyperlipidemia

COMPLETED PHASE3

Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function

NCT03001817

Severe Hypertriglyceridemia

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dyslipidemias

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment A

K-877 ER 0.2 mg/day (once daily)

Group Type EXPERIMENTAL

K-877 ER 0.2 mg/day (once daily)

Intervention Type DRUG

K-877 ER 0.2 mg tablet

Treatment B

K-877 ER 0.4 mg/day (once daily)

Group Type EXPERIMENTAL

K-877 ER 0.4 mg/day (once daily)

Intervention Type DRUG

K-877 ER 0.4 mg tablet

Control A

K-877 IR 0.2 mg/day (twice daily)

Group Type ACTIVE_COMPARATOR

K-877 IR 0.2 mg/day (twice daily)

Intervention Type DRUG

K-877 IR 0.1 mg tablet

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

K-877 ER 0.2 mg/day (once daily)

K-877 ER 0.2 mg tablet

Intervention Type DRUG

K-877 ER 0.4 mg/day (once daily)

K-877 ER 0.4 mg tablet

Intervention Type DRUG

K-877 IR 0.2 mg/day (twice daily)

K-877 IR 0.1 mg tablet

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Pemafibrate ER 0.2 mg/day (once daily) Pemafibrate ER 0.4 mg/day (once daily) Pemafibrate IR 0.2 mg/day (twice daily)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients with dyslipidemia had to be age 20 years or older at written informed consent
2. Patients who have received dietary or exercise guidance from 12 weeks or more prior to Screening
3. Patients with the fasting serum TG \>= 200 mg/dL twice consecutively at Screening

Exclusion Criteria

1. Patients with a fasting serum TG \> 1000 mg/dL at Screening
2. Patients who require administration of prohibited drugs during the clinical trial period after written informed consent
3. Patients with uncontrolled thyroid disease
4. Patients with type 1 diabetes and uncontrolled diabetes \[HbA1c(NGSP) \>= 8.0 % at Screening\]
5. Patients with uncontrolled hypertension (SBP \>= 160 mmHg or DBP \>= 100 mmHg)
6. Patients with an AST or ALT three times the upper limit at Screening
7. Patients with an CK five times the upper limit at Screening
8. Patients with cirrhosis or those with biliary obstruction
9. Patients with acute myocardial infarction within 3 months before obtaining informed consent
10. Patients with heart failure class III or higher according to NYHA cardiac function classification
11. Patients with malignant tumor or those who are judged to have a high risk of recurrence
12. Patients with a history of serious drug allergies (anaphylactic shock, etc.)
13. Pregnant women, lactating women, women planning to become pregnant or lactating during the study period, or pregnant women who do not use specific contraceptive methods
14. Patients who have collected 400 mL or more of whole blood within 16 weeks, or 200 mL or more of whole blood within 4 weeks, or blood samples (plasma and platelet components) within 2 weeks before Screening
15. Patients who have received K-877 (pemafibrate)
16. Patients who participate in other clinical trials at the time of written informed consent and who received medication or who have received clinical trials other than placebo for less than 16 weeks
17. Patients who have been determined inappropriate by the investigator, etc

Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No